Issued by BD - Becton, Dickinson and Company
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company’s 2020 Sustainability Goals.
FRANKLIN LAKES, N.J., July 12, 2018 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company’s 2020 Sustainability Goals.
BD’s sustainability strategy is driven by its purpose – advancing the world of health – and focuses on four priorities:
Highlights from this year’s progress report include:
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
# # #
BD Public Relations
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.
More from BD - Becton, Dickinson and Company